Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
Active, not recruiting · Phase 2 · NCT03282396
Conditions: Mantle Cell Lymphoma
At a glance
- Research payments reported, 2025
- $2.4M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 20
About the trial
- Sponsor
- M.D. Anderson Cancer Center (with National Cancer Institute (NCI))
- Tested
- Ibrutinib (drug)
- Dates
- Started 2020-06-08; completion 2028-02-28
- Results posted
- Not yet
This phase II trial studies how well ibrutinib works in treating participants with untreated high risk smoldering mental cell lymphoma. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
From ClinicalTrials.gov, last updated 2026-07-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $2.4M in research payments for this study in 2025 (4 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $2.4M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.